AN ADJUVANT FORMULATION PREPARED FOR SYMPTOMATIC TREATMENT OF SCHIZOPHRENIA
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: GABAA Catecholamines

description: The present invention herewith is related to a an adjuvant formulation prepared for symptomatic treatment of schizophrenia. <strong>Background of the Related Technology</strong> Today schizophrenia; is defined as a psychological disease which usually manifests itself during teenage years and where important disorders are observed in mentality, perception and behavior, and the patient refrains from any kind or relation with others and realities and lives within its own world. What is meant here is not a double personality, but the person believes in two different realities at the same time. While the “actual reality” corresponds to perception of a normal, average person, the “second reality” is a reality that generally is based on a certain system which cannot be understood by a healthy person. The frequency of development of schizophrenia in one’s full life is 0,5-1% in the general population. However among people who have schizophrenic relatives with blood tie, the occurrence rate is higher than the normal average among the population. While the role of genetic factors involving schizophrenia is well defined, this disease is not related only to genetic factors, but may develop with combination of various conditions. In other words, schizophrenia is a complex disease where both genetic and environmental factors play a role in its manifestation. At present, a multi-dimensional approach is considered to be useful in treatment of schizophrenia. Current treatments principally are based on using anti-psychotic drugs. This treatment is usually accompanied with psycho-therapies and other psycho-social approaches. It is considered that the anti-psychotic drugs act over dopamine, in a way confirming the hypothesis involving dopamine in schizophrenia. It might be required to hospitalize the patients for treatment in the acute period of this disease. The invention presented herewith with no “WO 1997/003071", with title "Derivatives of Heterocyclic Carboxamide and Their Use in Medical Treatment" and under classification number “C07D 405/14", is related to compositions with formula (I) and their pharmaceutically acceptable salts. In the referred formula A is methylene or O; B is methylene or O; g is 0, 1, 2, 3 or 4; R<sub>1</sub> is a substituent depending on preference; U is an alkylene chain that is substituted by one or more alkyl; Q is a divalent group that contains nitrogen atoms; and T represents CO.HET that is used in treatment of central nervous system disorders including, depression, anxiety, psychosis (e.g. schizophrenia), tardive dyskinesia, Parkinson’s disease, obesity, high blood pressure, Tourette’s syndrome, sexual function disorders, drug addiction, drug abuse, cognition disorders, Alzheimer’s disease, dementia based on senility, disorders related to obsessive behavior, panic attack crisis, social phobia, nutritional disorder and anorexia, Again the invention presented herewith with no “WO 1998/011890", with title "Using Benzopyranols in Treatment of Neurological Disorders” and under classification number “A61K 31/35", is related to beneficial benzopyran derivatives and related agents used for treatment and/or prophylaxis of Huntingdon’s Chorea, schizophrenia; AIDS, irregular sleep (including circadian arrhythmia, insomnia and narcolepsy), tics, (e.g., Giles de la Tourette Syndrome), traumatic brain damage, tinnitus, neuralgia, neuropathic pain, tooth ache, cancer pain; degenerative disorders like neurological disorders related to inappropriate neuron activity that results in neuro-dysthesia, like muscle hardness (spasticity) and temporomandibular joint dysfunction, ataxia, multiple sclerosis (MS) and motor nerve disease as well as diabetes. Again the invention presented herewith with no “WO 2000/021930", with title "(+)-alpha-(2,3-dimethoxyphenyl)- 1-(2-(4-fluorophenyl)ethyl)-4- piperidine methanol esters" and under classification number “C07D 211/22", is related to (+) -alpha- (2,3-dimethoxyphenyl) (1-2-(4-fluorophenyl) ethyl ) -4- piperidine methanol esters of formula (I) (here R is C4-C20 alkyl), their pharmaceutical formulations and methods related to production and use of such esters. These compounds antagonize the effect of serotonin at 5HT2A receptor and is beneficial in treatment of various cases of psychosis like schizophrenia. Again the invention presented herewith with no “EP2391625B1", with title "New Adenosine Receptor Ligands and Their Use” and under classification number “C07D 471/04", is related to providing new compounds that have a high affinity to adenosine A2A receptors. Also in diseases like Alzheimer’s Disease, Parkinson’s disease, or attention deficit hyperactivity disorder (ADHD), Huntington’s disease, neuroprotection, schizophrenia, anxiety disorders and pain, where it may be useful in the form where the signal paths of adenosine A2A receptors are partially or fully inactive, and it provides antagonists to the adenosine A2A receptors for prophylaxis and/or treatment of diseases or disorders and also is related to using these for treatment of the referred diseases. In addition, the present invention herewith is related to compounds that have high affinity to adenosine A2A receptors in treatment and/or prophylaxis of diseases and disorders where it will be useful to have part or all of the adenosine A2A receptors inactive and also is related to pharmaceutical compositions containing such new compounds. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended for symptomatic treatment of schizophrenia. <strong>Objective of the Invention</strong> To overcome the disadvantages referred in the Background of the Related Technology, One objective of the present invention is suppression of production of catecholamine secreted from adrenal medulla; One other objective of the invention is to trigger production of gaba; One other objective of the invention is to enhance gabaergic receptor sensitivity; The present invention which is aimed to achieve the above-mentioned advantages, is intended for symptomatic treatment of schizophrenia and is an adjuvant formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 11-ketoethyl-difluoro-anulen, 7-beta-anulen. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention is related to an adjuvant formulation prepared for symptomatic treatment of schizophrenia. The referred formulation, suppresses production of catecholamine secreted from adrenal medulla, triggers production of gaba and enhances gabaergic receptor sensitivity. Formulation related to the present invention contains; 11-ketoethyl-difluoro-anulen, 7-beta-anulen. The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 1-99% of 11-ketoethyl-difluoro-anulen, 99-1% of 7-beta-anulen. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time is related to using the above-referred formulation for symptomatic treatment of schizophrenia and manufacturing it for such purpose. <strong>CLAIMS</strong> An adjuvant formulation intended for symptomatic treatment of schizophrenia, which consists of combining the components selected from the group 11-ketoethyl-difluoro-anulen, 7-beta-anulen in a single form or in combinations thereof. The formulation of Claim 1 which is characterized by containing 1-99% of 11-ketoethyl-difluoro-anulen by weight. The formulation of Claim 1 which is characterized by containing 99-1% of 7-beta-anulen by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 11-ketoethyl-difluoro-anulen, 7-beta-anulen from any one as given in Claims 2-3 in manufacturing the adjuvant formulation intended for symptomatic treatment of schizophrenia. <strong>SUMMARY</strong> <strong>AN ADJUVANT FORMULATION PREPARED FOR SYMPTHOMATIC TREATMENT OF SCHIZOPHRENIA </strong> The present invention is related to an adjuvant formulation prepared for symptomatic treatment of schizophrenia. The referred formulation, suppresses production of catecholamine secreted from adrenal medulla, triggers production of gaba and enhances gabaergic receptor sensitivity.